Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer's Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2010 Sep 15

PMID 20838618

Citations 86

Authors

Giuseppe Astarita

Kwang-Mook Jung

Nicole C Berchtold

Vinh Q Nguyen

Daniel L Gillen

Elizabeth Head

Carl W Cotman

Daniele Piomelli

Affiliations

Soon will be listed here.

Abstract

Reduced brain levels of docosahexaenoic acid (C22:6n-3), a neurotrophic and neuroprotective fatty acid, may contribute to cognitive decline in Alzheimer's disease. Here, we investigated whether the liver enzyme system that provides docosahexaenoic acid to the brain is dysfunctional in this disease. Docosahexaenoic acid levels were reduced in temporal cortex, mid-frontal cortex and cerebellum of subjects with Alzheimer's disease, compared to control subjects (P = 0.007). Mini Mental State Examination (MMSE) scores positively correlated with docosahexaenoic/α-linolenic ratios in temporal cortex (P = 0.005) and mid-frontal cortex (P = 0.018), but not cerebellum. Similarly, liver docosahexaenoic acid content was lower in Alzheimer's disease patients than control subjects (P = 0.011). Liver docosahexaenoic/α-linolenic ratios correlated positively with MMSE scores (r = 0.78; P<0.0001), and negatively with global deterioration scale grades (P = 0.013). Docosahexaenoic acid precursors, including tetracosahexaenoic acid (C24:6n-3), were elevated in liver of Alzheimer's disease patients (P = 0.041), whereas expression of peroxisomal d-bifunctional protein, which catalyzes the conversion of tetracosahexaenoic acid into docosahexaenoic acid, was reduced (P = 0.048). Other genes involved in docosahexaenoic acid metabolism were not affected. The results indicate that a deficit in d-bifunctional protein activity impairs docosahexaenoic acid biosynthesis in liver of Alzheimer's disease patients, lessening the flux of this neuroprotective fatty acid to the brain.

Citing Articles

Compound-Specific Isotope Analysis as a Potential Approach for Investigation of Cerebral Accumulation of Docosahexaenoic Acid: Previous Milestones and Recent Trends.

Ali A, Hachem M, Ahmmed M Mol Neurobiol. 2024; .

PMID: 39633088 DOI: 10.1007/s12035-024-04643-1.

SIRT6-dependent functional switch via K494 modifications of RE-1 silencing transcription factor.

Zaretsky A, Venzor A, Eremenko E, Stein D, Smirnov D, Rabuah Y Cell Death Dis. 2024; 15(11):798.

PMID: 39511137 PMC: 11543946. DOI: 10.1038/s41419-024-07160-0.

Multifactor Analyses of Frontal Cortex Lipids in the APP/PS1 Model of Familial Alzheimer's Disease Reveal Anomalies in Responses to Dietary n-3 PUFA and Estrogenic Treatments.

Diaz M Genes (Basel). 2024; 15(6).

PMID: 38927745 PMC: 11202691. DOI: 10.3390/genes15060810.

The Connection between Chronic Liver Damage and Sporadic Alzheimer's Disease: Evidence and Insights from a Rat Model.

Mani R, Dogra N, Katare D Brain Sci. 2023; 13(10).

PMID: 37891760 PMC: 10605053. DOI: 10.3390/brainsci13101391.

miRNAs and Stem Cells as Promising Diagnostic and Therapeutic Targets for Alzheimer's Disease.

Elzayat E, Shahien S, El-Sherif A, Hosney M J Alzheimers Dis. 2023; 94(s1):S203-S225.

PMID: 37212107 PMC: 10473110. DOI: 10.3233/JAD-221298.

References

Martinez M . Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res. 1992; 583(1-2):171-82. DOI: 10.1016/s0006-8993(10)80021-6. View

Lukiw W, Cui J, Marcheselli V, Bodker M, Botkjaer A, Gotlinger K . A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005; 115(10):2774-83. PMC: 1199531. DOI: 10.1172/JCI25420. View

LaFerla F, Green K, Oddo S . Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007; 8(7):499-509. DOI: 10.1038/nrn2168. View

Bazan N, Scott B, Reddy T, Pelias M . Decreased content of docosahexaenoate and arachidonate in plasma phospholipids in Usher's syndrome. Biochem Biophys Res Commun. 1986; 141(2):600-4. DOI: 10.1016/s0006-291x(86)80215-7. View

Green K, Martinez-Coria H, Khashwji H, Hall E, Yurko-Mauro K, Ellis L . Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci. 2007; 27(16):4385-95. PMC: 6672302. DOI: 10.1523/JNEUROSCI.0055-07.2007. View

Rapoport S, Rao J, Igarashi M . Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot Essent Fatty Acids. 2007; 77(5-6):251-61. PMC: 2725409. DOI: 10.1016/j.plefa.2007.10.023. View

Martinez M . Severe deficiency of docosahexaenoic acid in peroxisomal disorders: a defect of delta 4 desaturation?. Neurology. 1990; 40(8):1292-8. DOI: 10.1212/wnl.40.8.1292. View

Innis S . Dietary omega 3 fatty acids and the developing brain. Brain Res. 2008; 1237:35-43. DOI: 10.1016/j.brainres.2008.08.078. View

HAINING J, Legan J . Catalase turnover in rat liver and kidney as a function of age. Exp Gerontol. 1973; 8(2):85-91. DOI: 10.1016/0531-5565(73)90018-1. View

10.

Yilmaz Y, Ozdogan O . Liver disease as a risk factor for cognitive decline and dementia: an under-recognized issue. Hepatology. 2009; 49(2):698. DOI: 10.1002/hep.22752. View

11.

Scott B, Bazan N . Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc Natl Acad Sci U S A. 1989; 86(8):2903-7. PMC: 287028. DOI: 10.1073/pnas.86.8.2903. View

12.

Corrigan F, Horrobin D, SKINNER E, Besson J, Cooper M . Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol. 1998; 30(2):197-207. DOI: 10.1016/s1357-2725(97)00125-8. View

13.

Calon F, Lim G, Yang F, Morihara T, Teter B, Ubeda O . Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 2004; 43(5):633-45. PMC: 2442162. DOI: 10.1016/j.neuron.2004.08.013. View

14.

Bazan N . Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci. 2006; 29(5):263-71. DOI: 10.1016/j.tins.2006.03.005. View

15.

Cummings J . Alzheimer's disease. N Engl J Med. 2004; 351(1):56-67. DOI: 10.1056/NEJMra040223. View

16.

Jiang L, Kurosawa T, Sato M, Suzuki Y, Hashimoto T . Physiological role of D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein. J Biochem. 1997; 121(3):506-13. DOI: 10.1093/oxfordjournals.jbchem.a021615. View

17.

Cunnane S, Plourde M, Pifferi F, Begin M, Feart C, Barberger-Gateau P . Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res. 2009; 48(5):239-56. DOI: 10.1016/j.plipres.2009.04.001. View

18.

Han X, Holtzman D, McKeel Jr D . Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem. 2001; 77(4):1168-80. DOI: 10.1046/j.1471-4159.2001.00332.x. View

19.

Prasad M, Lovell M, Yatin M, Dhillon H, Markesbery W . Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res. 1998; 23(1):81-8. DOI: 10.1023/a:1022457605436. View

20.

Soderberg M, Edlund C, Kristensson K, Dallner G . Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids. 1991; 26(6):421-5. DOI: 10.1007/BF02536067. View